Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

Building on their existing collaboration, the companies have signed a new agreement to focus on lead optimization of drug candidates identified by Variational AI’s Enki™ generative AI platform and ...
Cure Today

Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer

ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
EurekAlert!

Human ATR-ATRIP complex structure discloses mechanisms of action and inhibition

Cryo-EM reconstructions of the human ATR–ATRIP complex show how clinical small-molecule inhibitors like VE-822 and RP-3500 bind to and inhibit ATR activity. A research team led by Prof. Gang Cai and ...
BioWorld

Rakovina makes progress on ATR inhibitor program

Rakovina Therapeutics Inc. has reported progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (ataxia telangiectasia and Rad3-related) inhibitors designed to disrupt ...
FOX8 Cleveland

Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Initial Phase 2 data from ongoing trial for ART0380 in platinum resistant ovarian cancer is expected for the gemcitabine combination in H1 2025 and for the irinotecan combination in ATM deficient ...
Nasdaq

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

BRANFORD, Conn.--(BUSINESS WIRE)-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...